News > DGCI grants approval for clinical trials of Sputnik V in India
DGCI grants approval for clinical trials of Sputnik V in India
Northeast Now | 17/10/2020 07:44 PM | Click to read full article
Dr. Reddy’s, a global pharmaceutical company headquartered in India, has been granted approval by the Drug Controller General of India (DCGI) to conduct clinical trials of COVID19 vaccine Sputnik V.
Dr. Reddy’s has been allowed to conduct phase 2 and 3 clinical human trials of the COVID19 vaccine made by Russia. Sputnik V, which is an adenovirus vector-based vaccine has been developed by the Gamaleya Scientific Research Institute of Epidemiology and Microbiology.
